Portfolio

The Cureteq portfolio comprises assets in portfolio companies, Oncoteq, focusing on oncology indications, and a new portfolio company still in stealth mode.

The Cureteq portfolio currently comprises assets in two companies, Oncoteq, focusing on oncology, and a company still in stealth mode.

Oncoteq is founded and seeded by Cureteq and headquartered in Zug, Switzerland, and will be responsible for the development of TEQ101.

Read about Oncoteq

Portfolio company still in stealth mode

Oncoteq

TEQ101
MetAP2 inhibition
Renal cell carcinoma
 
TEQ102
CD30
CD30+ Lymphomas
 
TEQ103
ER alpha
Breast cancer
 
Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings".
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year.
Save Accept all